Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quality of Bowel Preparation in the General Population.

Medicina (Kaunas, Lithuania)·2026

Same author

The interplay between body mass index, motivation for food consumption, and noncommunicable diseases in the European population: A cross-sectional study.

PloS one·2025

Same author

CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.

Acta clinica Croatica·2025

Same author

Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn's Disease Treated with Anti-TNF (Adalimumab).

Case reports in gastrointestinal medicine·2023

Same author

Dissemination of Clinical <i>Acinetobacter baumannii</i> Isolate to Hospital Environment during the COVID-19 Pandemic.

Pathogens (Basel, Switzerland)·2023

Same author

Emotions and Food Consumption: Emotional Eating Behavior in a European Population.

Foods (Basel, Switzerland)·2023

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

[Chronic hepatitis B therapy].

Miro Morović¹, Biserka Troselj-Vukić, Ivo Klarin

¹Department of Infectious Diseases, Zadar General Hospital, Zadar, Croatia.

Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti

|March 5, 2010

Summary

Chronic hepatitis B treatments, including interferon and nucleoside/nucleotide analogues, offer distinct benefits and drawbacks. While some patients achieve remission with interferon, analogues effectively suppress viral DNA but may require lifelong therapy and can lead to resistance.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jun 15, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Chronic hepatitis B (CHB) is a significant global health concern, leading to cirrhosis and hepatocellular carcinoma in a substantial number of patients.
Current therapeutic strategies aim to manage viral replication and prevent disease progression.

Purpose of the Study:

To review the efficacy and limitations of current standard treatments for chronic hepatitis B.
To compare the benefits and drawbacks of interferon-based therapy versus nucleoside/nucleotide analogues.

Main Methods:

Literature review of existing studies on chronic hepatitis B treatments.
Analysis of treatment outcomes, including remission rates, viral suppression, resistance development, and duration of therapy.

Main Results:

Pegylated interferon alfa-2a can induce long-term remission in approximately one-third of selected HBeAg-positive patients without resistance.
Nucleoside/nucleotide analogues (entecavir, tenofovir, adefovir, telbivudine, lamivudine) achieve undetectable HBV DNA levels in 70-90% of patients.
Interferon is ineffective for the majority of patients, while analogue therapy often requires long-term or lifelong treatment and carries a risk of resistance.

Conclusions:

Both interferon and nucleoside/nucleotide analogues have specific advantages and disadvantages in managing chronic hepatitis B.
Treatment selection requires careful consideration of patient characteristics, desired outcomes, and potential for resistance.